Early research (Phase 1)Ended earlyNCT06052852
What this trial is testing
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Who this might be right for
Triple Negative Breast CancerClear Cell Renal Cell CarcinomaOvarian Cancer+4 more
Bolt Biotherapeutics, Inc. 17